Biosimilar abatacept: Ph I started

Momenta began a double-blind, U.K. Phase I trial to compare single doses of M834 vs. Orencia from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) in about 300 healthy volunteers. The trial start ...